Vacature Viral Vector Manufacturing Cdmo

Pre-clinical manufacturing | Clinical and commercial manufacturing | Analytical and Regulatory services

Viral vectors are a proven approach that is increasingly being used in oncolytic immunotherapies, cell and gene therapies, therapeutic and prophylactic vaccines. When it comes to their manufacturing, you need a CDMO with the expertise and infrastructure to scale viral vector manufacturing, produce high yields , and provide you with your product within budget and on time . Explore HALIX's track record and viral vector manufacturing capabilities below.

• Viral Vectors and Vaccines
• Recombinant Proteins and Antibodies
• Aseptic Fill / Finish and Lyophilization

Preclinical viral vector manufacturing

Our pre-clinical viral vector manufacturing activities are geared towards process transfer, development, and supporting scale-up for eventual GMP manufacturing. Through small scale process confirmation runs and full scale engineering demonstration runs , we can produce material for pre-clinical non-human use to support formal toxicology studies, analytical development, phase appropriate analytical method qualification or validation, reference standards, as well as stability studies. These data can then be used to support definition of IND / CTA CMC content.

• Tech batches: upscaled viral vector production for evaluation of technological capabilities.
• TOX batches: upscaled viral vector production to deliver material for use in toxicological studies.

• Testing and characterization: safety testing, bio-assays, bio-chemical assays, potency testing, stability testing.

• Regulatory support: dossier development pre-IND, IMPD.

Clinical viral vector manufacturing

We perform the cGMP manufacture of viral vector drug substance and drug product for all phases of clinical trials (phase 1 - 3), meeting regulatory compliance globally.

Cell and seed banks

• Production, safety testing and characterization of research, master and working cell banks (MCB/WCB).
• Production, safety testing and characterization of master and (MVS/WVS).

Bulk viral vector drug substance

• Cell culturing (USP): clinical drug substance viral vector manufacturing based on mammalian cell culturing in roller bottles, cell factories, and (fed)batch single-use bioreactors.
• Purification/formulation (DSP): chromatographic separation, filtration, TFF, dead end filtration, low speed gradient centrifugation as well as virus inactivation and removal.

• Aseptic fill and finish of viral vectors and vaccines, freeze-drying of drug products, as well as labeling and secondary packaging of biopharmaceutical products with custom layouts and randomization.

Commercial viral vector manufacturing

We are GMP licensed and approved by the Dutch regulatory authorities (IGJ), in accordance with EMA, for the manufacture of drug substance and drug product batches used for commercial (licensed product) purposes. Next to that, we also provide the full scope of process validation and support studies using validated analytical methods, to support your product licensure applications (BLA, MAA, etc.).

Cell and seed banks

• Production, safety testing and characterization of research, master and working cell banks (MCB/WCB).
• Production, safety testing and characterization of master and working virus seed banks (MVS/WVS).

Bulk viral vector drug substance

• Cell culturing (USP): commercial drug substance viral vector manufacturing based on mammalian cell culturing in roller bottles, cell factories, T-flasks, (fed)batch and perfusion single-use bioreactors.
• Purification/formulation (DSP): chromatographic separation, filtration, TFF, dead end filtration, low speed gradient centrifugation as well as virus inactivation and removal.

• Aseptic fill and finish of viral vectors and vaccines, freeze-drying of drug products, as well as labeling and secondary packaging of biopharmaceutical products with custom layouts and randomization.

We are continually expanding our internal analytical development and quality control (QC) capabilities, providing analytical support to our client's projects. Analytical methods are then qualified and validated according to the phase of clinical development & regulatory expectations, to perform QC release and stability testing.

If necessary, we will outsource analytical testing to a panel of qualified vendors under our quality management system and report the results on a certificate of analysis.

Preclinical viral vector manufacturing

Our pre-clinical viral vector manufacturing activities are geared towards process transfer, development, and supporting scale-up for eventual GMP manufacturing. Through small scale process confirmation runs and full scale engineering demonstration runs , we can produce material for pre-clinical non-human use to support formal toxicology studies, analytical development, phase appropriate analytical method qualification or validation, reference standards, as well as stability studies. These data can then be used to support definition of IND / CTA CMC content.

• Tech batches: upscaled viral vector production for evaluation of technological capabilities.
• TOX batches: upscaled viral vector production to deliver material for use in toxicological studies.

• Testing and characterization: safety testing, bio-assays, bio-chemical assays, potency testing, stability testing.

• Regulatory support: dossier development pre-IND, IMPD.

Clinical (Phase I-III) manufacturing

Clinical viral vector manufacturing

We perform the cGMP manufacture of viral vector drug substance and drug product for all phases of clinical trials (phase 1 - 3), meeting regulatory compliance globally.

Cell and seed banks

• Production, safety testing and characterization of research, master and working cell banks (MCB/WCB).
• Production, safety testing and characterization of master and (MVS/WVS).

Bulk viral vector drug substance

• Cell culturing (USP): clinical drug substance viral vector manufacturing based on mammalian cell culturing in roller bottles, cell factories, and (fed)batch single-use bioreactors.
• Purification/formulation (DSP): chromatographic separation, filtration, TFF, dead end filtration, low speed gradient centrifugation as well as virus inactivation and removal.

• Aseptic fill and finish of viral vectors and vaccines, freeze-drying of drug products, as well as labeling and secondary packaging of biopharmaceutical products with custom layouts and randomization.

Commercial viral vector manufacturing

We are GMP licensed and approved by the Dutch regulatory authorities (IGJ), in accordance with EMA, for the manufacture of drug substance and drug product batches used for commercial (licensed product) purposes. Next to that, we also provide the full scope of process validation and support studies using validated analytical methods, to support your product licensure applications (BLA, MAA, etc.).

Cell and seed banks

• Production, safety testing and characterization of research, master and working cell banks (MCB/WCB).
• Production, safety testing and characterization of master and working virus seed banks (MVS/WVS).

Bulk viral vector drug substance

• Cell culturing (USP): commercial drug substance viral vector manufacturing based on mammalian cell culturing in roller bottles, cell factories, T-flasks, (fed)batch and perfusion single-use bioreactors.
• Purification/formulation (DSP): chromatographic separation, filtration, TFF, dead end filtration, low speed gradient centrifugation as well as virus inactivation and removal.

• Aseptic fill and finish of viral vectors and vaccines, freeze-drying of drug products, as well as labeling and secondary packaging of biopharmaceutical products with custom layouts and randomization.

We are continually expanding our internal analytical development and quality control (QC) capabilities, providing analytical support to our client's projects. Analytical methods are then qualified and validated according to the phase of clinical development & regulatory expectations, to perform QC release and stability testing.

If necessary, we will outsource analytical testing to a panel of qualified vendors under our quality management system and report the results on a certificate of analysis.

cGMP viral vector production services and capabilities

Our fully licensed production facility in the Netherlands allows for flexible and scalable contract development and cGMP production from preclinical to commercial scale products. Our production capabilities cover the whole manufacturing spectrum and include:

• Strong experience in adherent and suspension cell lines
• Upstream processing, from small scale up to 1,000 L scale
• Purification using depth filtration, tangential flow filtration (TFF) and chromatography systems
• Single use disposable equipment
• Large scale manufacturing of BSL1, BSL2 and BSL3 viruses

• Development using Quality by Design (QbD) principles
• Analytical method development and optimization
• Analytical method qualification and QC method validation
• Early stage process development and Design of Experiment (DoE)
• Process optimization and process scale-up
• scale down models and viral clearance studies
• Early and late stage process
• Engineering toxicology batches and GLP TOX study batches
• GMP manufacturing of clinical and commercial Drug Substance and Drug Product , including cell banks and virus seeds
• Process Performance Qualification (PPQ) and supporting studies

COMPLIANCE AND QUALITY

• EU GMP grade C production suites for drug substance manufacturing
• Independent air treatment per clean room
• Unidirectional flow for personnel and materials
• Suitable for decontamination using VHP
• GMP and commercial manufacturing certificate and regular GMP inspections
• Comprehensive quality assurance and Quality Management System (QMS), in compliance with EUGMP, FDA, ICH and other industry standards and guidelines

• Short communication channels by providing direct access to key HALIX project team members
• Project supervision by Sr. management of the customer & scientifically qualified Sr. management from HALIX
• Regular project team meetings ensure progress, alignment, mitigate risks and proactively manage critical activities
• Specialized and interdisciplinary teams fully committed to the project's success
• One project manager as single use of contact

We support you in developing and commercializing recombinant proteins and antibodies, enabling the treatment and prevention of life-threatening conditions.

HALIX B.V. Tinbergenweg 1, 2333 BB Leiden, The Netherlands

Functie:	viral vector manufacturing cdmo
Startdatum:	16-05-2024
Ervaring:	Ervaren
Educatielevel:	HBO
Contracttype:	Vast
Salaris:	onbekend – onbekend
Uren per week:	1 – 40

Heb je interesse in deze vacature en wil je graag op deze functie solliciteren? Neem dan contact op met HALIX via onbekend of onbekend. Of bezoek hun website onbekend.